CAJ | 학술논문

目的：比较不同剂量伊立替康联合顺铂(DDP)方案二线治疗小细胞肺癌(SCLC)的近期疗效、无进展生存期及不良反应。方法80例SCLC患者,随机分为低剂量伊立替康组(40例)和高剂量伊立替康组(40例),分别接受低剂量伊立替康和高剂量伊立替康方案化疗。要研究终点为无进展生存期(progression-free survival, PFS),客观反应率(response rate, RR)和不良反应。结果低剂量伊立替康组RR 52.5%,中位PFS为6.2个月；高剂量伊立替康组RR 60.0%,中位PFS为5.5个月,两组PFS比较差异无统计学意义(P>0.05)。两组主要不良反应均为骨髓抑制和腹泻,比较差异有统计学意义(P<0.05)。结论低剂量伊立替康与高剂量伊立替康二线治疗SCLC 客观疗效及PFS 相当,但骨髓抑制及腹泻明显低于高剂量组。
목적：비교불동제량이립체강연합순박(DDP)방안이선치료소세포폐암(SCLC)적근기료효、무진전생존기급불량반응。방법80례SCLC환자,수궤분위저제량이립체강조(40례)화고제량이립체강조(40례),분별접수저제량이립체강화고제량이립체강방안화료。요연구종점위무진전생존기(progression-free survival, PFS),객관반응솔(response rate, RR)화불량반응。결과저제량이립체강조RR 52.5%,중위PFS위6.2개월；고제량이립체강조RR 60.0%,중위PFS위5.5개월,량조PFS비교차이무통계학의의(P>0.05)。량조주요불량반응균위골수억제화복사,비교차이유통계학의의(P<0.05)。결론저제량이립체강여고제량이립체강이선치료SCLC 객관료효급PFS 상당,단골수억제급복사명현저우고제량조。
Objective To compare the efficacy, progression free survival and adverse reactions of different doses of irinotecan combined with cis-diammin-odichloroplatinum Ⅱdichloridlein (DDP) second-line treatment of small cell lung cancer (SCLC). Methods A total of 80 patients were randomly divided into the low dose irinotecan group (40 cases) and the high dose irinotecan group (40 cases). Progression-free survival (PFS), response rate (RR), and adverse reactions were analyzed. Results The RR was 52.5%and the median PFS were 6.2 months in the low dose irinotecan group, and the RR was 60.0%and the median PFS were 5.5 months in the high dose irinotecan group. The difference between PFS in the two groups was not statistically significant (P>0.05). The main adverse reactions of the two groups were all myelosuppression and diarrhea, and the difference had statistical significance (P<0.05). Conclusion The curative effect and PFS of the low dose irinotecan and the high dose irinotecan in second-line therapy for SCLC are equivalent. The incidence of myelosuppression and diarrhea of the low dose irinotecan are lower than the high dose irinotecan.